Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM) Alters disease progression and suppresses endomysial inflammation
Publication
, Conference
Dalakas, MC; Rakocevic, G; McElroy, B; Salaftheh, MK; Schmidt, J; Harris-Love, M; Shrader, J; Levy, E; Kirk, AD
Published in: ANNALS OF NEUROLOGY
January 1, 2007
Duke Scholars
Published In
ANNALS OF NEUROLOGY
ISSN
0364-5134
Publication Date
January 1, 2007
Volume
62
Start / End Page
S60 / S61
Location
Washington, DC
Publisher
WILEY-LISS
Conference Name
132nd Annual Meeting of the American-Neurological-Association
Related Subject Headings
- Neurology & Neurosurgery
- 3209 Neurosciences
- 3202 Clinical sciences
- 1109 Neurosciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Dalakas, M. C., Rakocevic, G., McElroy, B., Salaftheh, M. K., Schmidt, J., Harris-Love, M., … Kirk, A. D. (2007). Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM) Alters disease progression and suppresses endomysial inflammation. In ANNALS OF NEUROLOGY (Vol. 62, pp. S60–S61). Washington, DC: WILEY-LISS.
Dalakas, Marinos C., Goran Rakocevic, Beverly McElroy, Mohammad K. Salaftheh, Jens Schmidt, Michael Harris-Love, Joseph Shrader, Ellen Levy, and Allen D. Kirk. “Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM) Alters disease progression and suppresses endomysial inflammation.” In ANNALS OF NEUROLOGY, 62:S60–61. WILEY-LISS, 2007.
Dalakas MC, Rakocevic G, McElroy B, Salaftheh MK, Schmidt J, Harris-Love M, et al. Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM) Alters disease progression and suppresses endomysial inflammation. In: ANNALS OF NEUROLOGY. WILEY-LISS; 2007. p. S60–1.
Dalakas, Marinos C., et al. “Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM) Alters disease progression and suppresses endomysial inflammation.” ANNALS OF NEUROLOGY, vol. 62, WILEY-LISS, 2007, pp. S60–61.
Dalakas MC, Rakocevic G, McElroy B, Salaftheh MK, Schmidt J, Harris-Love M, Shrader J, Levy E, Kirk AD. Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM) Alters disease progression and suppresses endomysial inflammation. ANNALS OF NEUROLOGY. WILEY-LISS; 2007. p. S60–S61.
Published In
ANNALS OF NEUROLOGY
ISSN
0364-5134
Publication Date
January 1, 2007
Volume
62
Start / End Page
S60 / S61
Location
Washington, DC
Publisher
WILEY-LISS
Conference Name
132nd Annual Meeting of the American-Neurological-Association
Related Subject Headings
- Neurology & Neurosurgery
- 3209 Neurosciences
- 3202 Clinical sciences
- 1109 Neurosciences
- 1103 Clinical Sciences